Replies to post #198 on BiondVax Pharmaceuticals Ltd (BVXV)

[midastouch017]

The Company announced positive preliminary safety results from the Phase 2b clinical trial of M-001, conducted in collaboration with the European UNISEC consortium[1]. Immunogenicity results, currently being processed by other UNISEC consortium entities, are expected by the end of Q2 2017.

Not too long a wait!